This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Biotech Stocks Expected to at Least Double

2. Cyclacel Pharmaceuticals (CYCC) develops mechanism-targeted drugs for human cancers, targeting the cell cycle in order to slow progression or shrink tumors. Cyclacel's second-quarter loss decreased 44% to $3.9 million, or 18 cents a share, as revenue fell 55%. Cyclacel has $20 million of cash and no debt. Its stock sells for a book value multiple of 4.3, a 19% discount to its peer average. It's expensive based on sales. Just two analysts follow the company, both rating its stock "buy." A median target of $5.25 suggests the stock will more than triple.

Bullish Scenario: Roth Capital Partners values the stock at $7, implying it will more than quadruple.

9 of 10

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $128.70 0.00%
FB $78.81 0.00%
GOOG $540.78 0.00%
TSLA $230.51 0.00%
YHOO $42.04 0.00%

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs